Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Institut Regional Du Cancer De Montpellier

Centre National De La Recherche Scientifique

Sorbonne Université

Université´ D'aix-marseille

Inserm (institut National De La Sante Et De La Recherche Medicale)

Institut Regional Du Cancer De Montpellier-val D'aurelle

Institut Paoli Calmettes

Gamamabs Pharma

Centre Regional De Lutte Contre Le Cancer “val D'aurelle-paul Lamarque”

Centre National De La Recherche Scientifique-cnrs

Oribase Pharma

Biomunex Pharmaceuticals

Centre Val D'aurelle—paul Lamarque

André Pelegrin

Isabelle Teulon

Christel Larbouret

Stephen D Gillies

Daniel Baty

Jean-Marc Barret

Bruno Robert

Pierre Martineau

Thierry Chardes

Bénédicte Fauvel

Jean-luc Teillaud

Gwénaël Cheve

Nadège Gaborit

Khalil Bouayadi

Jean-François Prost

Abdelhakim Kharrat

Myriam Chentouf

Olivier Dubreuil

Christian Larroque

Nathalie Di Clemente-Besse

Aziz Yasri

Wilhem Leconet

Yassamine Lazrek

Ghislaine Behar

Olivier Leger

Eugene Zhukovsky

Thierry Chardès

Stéphane Degove

David Azria

Maëva Chauvin

Martine Chartier

Philippe Gauthier

Mickaël Coelho

Pierre-emmanuel Gerard

Philippe Mondon

Nadège A Gaborit

In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic targets. Conversely, the role of the three MIS type I receptors (MISRI; ALK2, ALK3 and ALK6) in this cancer needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients' tumor ascites, the inventors found that ALK2 and ALK3 are the two main MISRIs involved in MIS signaling at low and high MIS concentrations, respectively. Moreover, high MIS concentrations were associated with apoptosis and decreased clonogenic survival, whereas low MIS concentrations improved cancer cell viability. Finally, the inventors showed that anti-MIS antibody B10 inhibited MIS pro-survival effect. These last results open the way to an innovative therapeutic approach to suppress MIS proliferative effect, instead of administering high doses of MIS to induce cancer cell apoptosis.

Anti-müllerian inhibiting substance antibodies and uses thereof

The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.

Anti-human-HER3 antibodies and uses thereof

The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody 'trastuzumab' (HERCEPTIN&#xae;) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody 'matuzumab' (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.

Combination therapy using anti-EGFR and anti-HER2 antibodies

The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-M&#xfc;llerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers.

Monoclonal antibodies and fragment thereof directed against the human anti-mullerian hormone type II receptor (AMHR-II)

The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.

Production of antibody formats and immunological applications of said formats

Monoclonal antibodies and fragment thereof directed against the human Anti-M&#xfc;llerian Hormone type II receptor (AMHR-II)

This invention relates to human anti-idiotypic antibody fragments, especially scFv, characterized by the ability to mimic Her-2/neu tumor associated antigen. These antibody fragments are promising candidates for active immunotherapy for cancer patients positive for Her-2/neu.

Human anti-idiotypic antibody fragments that mimic HER-2/neu

Growing community of inventors

Montpellier, France

André Pelegrin